Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib +/- Bevacizumab in Recurrent Endometrial or Ovarian Cancer with ARID1A Mutation
NCT05523440Phase 2Terminated
- Sponsor
- University of Oklahoma
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in endometrial cancer (EC) and ovarian cancer comparing Arm 1: Niraparib with Arm 2: Niraparib and Bevacizumab (2 arms). Primary endpoint: Objective Response Rate at 16 months. Started Feb 2023; status: terminated.
02
Drugs
niraparibbevacizumab
03
Conditions
endometrial cancer (EC)ovarian cancer
Beyond the preview
Go deeper on NCT05523440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523440.